Lexicon with a "Knockout" Punch

Tags: lxrx
10 Jan 4:01am
Posted by ZacksResearch
0 Comments
Read original blog entry

Lexicon Pharmaceuticals Inc. (LXRX) is focused on defining the functions of genes using the 'gene knockout' technology. Based on its proprietary technology, the company has attracted both drug-based collaborations and strategic equity investors.

The company is currently engaged in research and development of small molecule drugs in a broad area of diseases. We are pleased with the progress made by the company with its gene knockout technology and its '10TO10' clinical program.

Lexicon has three candidates in clinical studies and the company's cash position is relatively strong. We maintain our Buy rating on Lexicon Pharmaceuticals. Our price target is $3.50.

Read the full analyst report on LXRX




Get real-time market insights and profitable stock recommendations from the team of analysts at Zacks Equity Research. See all today’s Analyst Blog entries on Zacks.com.

Comments

Back to top

Post comment

Back to top

Post a comment

Please login to post a comment

About

ZacksResearch

Zacks Investment Research is one of the most highly regarded firms in the investment industry. Our firm has long believed that that quantitative models (like the Zacks Rank) can predict stock prices more accurately than individual analysts. However we also recognize that models are most effective when they are employed by analysts who have deep fundamental knowledge of the company and its industry. Consequently Zacks Equity Research combines Zacks quantitative models with the insight provided by an experienced team of 50 analysts to create superior long term stock recommendations. Discover all their timely insight and recommendations daily on Zacks.com.

Recent Entries